Metabolic Targets in Nonalcoholic Fatty Liver Disease.

94 These reductions in steatosis were associated with trends toward reductions in alanine aminotransferase (ALT), though these did not reach statistical significance ( P = .11 and P = .41 for 100 mg and 30 mg, respectively). 94 Trends toward increased total cholesterol (5% [ P = .14] and 4.4% [ P = .48] for 100 mg and 30 mg, respectively, placebo adjusted) and LDL cholesterol (10.2% [ P = .13] and 9.8% [ P = .28] for 100 mg and 30 mg, respectively) were also observed.

also in 111,027 other papers